MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Inflammation"

  • 2022 International Congress

    mGlu3 receptors in Parkinson’s disease as a candidate target for neuroprotective therapy: evidence from preclinical studies to human genetic.

    M. Alborghetti, L. Di Menna, V. Bruno, G. Battaglia, FE. Pontieri, E. Bianchini, M. Simmaco, M. Borro, F. Nicoletti (Rome, Italy)

    Objective: In a  toxicological model of mouse parkinsonism through chronic injection of MPTP, we examined whether the presence or absence of mGlu3 receptors affected neurodegeneration…
  • 2022 International Congress

    Parkin deficiency impairs mtDNA dynamics and propagates inflammation

    K. Wasner, S. Smajić, J. Ghelfi, S. Delcambre, C. Prada-Medina, E. Knappe, G. Arena, P. Mulica, G. Agyeah, A. Rakovic, I. Boussaad, K. Badanjak, J. Ohnmacht, J. Gérardy, M. Takanashi, J. Trinh, M. Mittelbronn, N. Hattori, C. Klein, P. Antony, P. Seibler, M. Spielmann, S. Pereira, A. Grünewald (Belvaux, Luxembourg)

    Objective: We sought to explore Parkin’s role in (i) averting neuronal mtDNA dyshomeostasis/release and (ii) the activation of downstream inflammatory processes. Background: Mutations in Parkin…
  • 2022 International Congress

    Increased Prevalence of Thyroid Disease in Cervical Dystonia

    L. Scorr, G. Kilic-Berkmen, A. Rosen, C. Yeo, J. Hanfelt, H. Jinnah (Atlanta, USA)

    Objective: This study evaluated the hypothesis that autoimmune disorders may be more common in cervical dystonia (CD) than neurological controls. Background: Although there are many…
  • 2022 International Congress

    Phosphorylated α-synuclein at serine residue 129 decreased in Parkinson’s disease patients taking 250mg of daily niacin for six months

    C. Wakade, M. Seamon, S. Purohit, J. Morgan, R. Chong (Augusta, USA)

    Objective: The main objective was to determine if α-synuclein could be modulated by niacin supplementation, contributing to improved Parkinson’s disease (PD) symptoms. Background: Niacin supplementation…
  • 2022 International Congress

    A Phase 1b study to test the safety, pharmacokinetics, and pharmacodynamics of a novel inflammasome inhibitor in early-stage Parkinson’s disease: Rationale and study design

    G. D'Urso, A. Thomann, J. Anzures-Cabrera, B. Zinnhardt, B. Ricci, M. Marchesi, V. Machado, E. Mracsko, N. Pavese, K. Marek, K. Brockmann, T. Simuni, N. Milani Muelhardt, G. Pagano (Basel, Switzerland)

    Objective: To describe the study design of a Phase 1b to test the safety, pharmacokinetics, and pharmacodynamics of a novel inflammasome inhibitor in individuals with…
  • 2022 International Congress

    4 YEARLONG POST PARTUM AUTOIMMUNE CHOREA AS INITIAL PRESENTATION OF INCOMPLETE SLE/APS

    W. Trillo Alvarez, J. Medina Suárez, J. Molina Acosta, A. Escalante Mercado, C. Ibañez Escalante, E. Carrillo Monteagudo, V. Medina Cerpa, E. Ramos Luza, P. Gonzales Romero, G. García Huamán (AREQUIPA, Peru)

    Objective: The aim is to report a case of a 4 yearlong postpartum autoimmune chorea secondary to incomplete SLE/APS. Background: Chorea is a movement disorder…
  • 2022 International Congress

    Inflammatory microglial and astroglial phenotype associated with pathological alpha-synuclein inclusions in the substantia nigra

    A. Stoll, M. Bensky, J. Patterson, C. Kemp, K. Steece-Collier, M. Hore, K. Luk, C. Sortwell (Grand Rapids, USA)

    Objective: To characterize neuroinflammatory gene expression in microglia and astrocytes associated with early alpha-synuclein (a-syn) inclusion formation. Background: Parkinson’s disease (PD) is characterized by alpha-synuclein…
  • 2022 International Congress

    Alteration of the fecal microbiota in Turkish patients with idiopathic Parkinson’s disease

    GBY. Babacan-Yildiz, CZK. Kayacan, IK. Karacan, BS. Sumbul, BE. Elibol, OG. Gelisin, OA. Akgul (ISTANBUL, Turkey)

    Objective: To determine whether the gut microbiota is altered in Turkish patients with Parkinson Disease (PD) and  the potential effect of gut microbiota on pre-motor…
  • 2022 International Congress

    In-vivo measurement of tau depositions in anti-IgLON5 disease with 18F-PI2620-PET

    H. Theis, GN. Bischof, I. Ayzenberg, N. Brüggemann, T. Grüter, J. Hammes, J. Lewerenz, F. Leypoldt, A. Drzezga, T. van Eimeren (Cologne, Germany)

    Objective: The aim of the study was to examine the potential of the second-generation tau-PET tracer 18F-PI2620 to detect tau deposition in anti-IgLON5 disease. Background:…
  • 2022 International Congress

    Movement disorders with phosphodiesterase 10A IgG autoimmunity

    C. Valencia-Sanchez, A. Mckeon, A. Zekeridou (Scottsdale, USA)

    Objective: To report four new cases of phosphodiesterase 10A (PDE10A) IgG neurological autoimmunity. Background: PDE10A IgG was recently identified as a biomarker of paraneoplastic neurological…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 28
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley